Literature DB >> 22565960

The many faces of Bruton's tyrosine kinase.

C Patrick McAtee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22565960     DOI： 10.1038/nbt.2200

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Companies in rapid pursuit of Btk immunokinase.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-03-07       Impact factor: 54.908

2.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962
  2 in total
  1 in total

1.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Authors:  Patrick F Smith; Janakan Krishnarajah; Philip A Nunn; Ron J Hill; Dane Karr; D Tam; Mohammad Masjedizadeh; Jens O Funk; Steve G Gourlay
Journal:  Br J Clin Pharmacol       Date:  2017-08-01       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.